Letetresgene autoleucel

DB17233InvestigationalCell transplant therapies

Letetresgene autoleucel: Overview.

Mechanism: Pharmacologically active on MHC class I HLA-A protein, Cancer/testis antigen 1, and Cancer/testis antigen 2
Curator reviewed
Also known as: NY-ESO TCR therapeutic · NY-ESO-1 T cell receptor · NY-ESO-1 TCR T · NY-ESO-1 TCR-T
Code names: GSK-3377794 · GSK 794

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Letetresgene autoleucel, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.